| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Experimental Medicine, University of Perugia, Perugia, Italy; and
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228
Dendritic cell (DC) tryptophan catabolism has emerged in recent years as a major mechanism of peripheral tolerance. However, there are features of this mechanism, initiated by IDO, that are still unclear, including the role of enzymes that are downstream of IDO in the kynurenine pathway and the role of the associated production of kynurenines. In this study, we provide evidence that 1) murine DCs express all enzymes necessary for synthesis of the downstream product of tryptophan breakdown, quinolinate; 2) IFN-
enhances transcriptional expression of all of these enzymes, although posttranslational inactivation of IDO may prevent metabolic steps that are subsequent and consequent to IDO; 3) overcoming the IDO-dependent blockade by provision of a downstream quinolinate precursor activates the pathway and leads to the onset of suppressive properties; and 4) tolerogenic DCs can confer suppressive ability on otherwise immunogenic DCs across a Transwell in an IDO-dependent fashion. Altogether, these data indicate that kynurenine pathway enzymes downstream of IDO can initiate tolerogenesis by DCs independently of tryptophan deprivation. The paracrine production of kynurenines might be one mechanism used by IDO-competent cells to convert DCs lacking functional IDO to a tolerogenic phenotype within an IFN--rich environment.
This article has been cited by other articles:
|
|
 |
|
  F. Fallarino, C. Volpi, T. Zelante, C. Vacca, M. Calvitti, M. C. Fioretti, P. Puccetti, L. Romani, and U. Grohmann IDO Mediates TLR9-Driven Protection from Experimental Autoimmune Diabetes J. Immunol., November 15, 2009; 183(10): 6303 - 6312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Onodera, M. H. Jang, Z. Guo, M. Yamasaki, T. Hirata, Z. Bai, N. M. Tsuji, D. Nagakubo, O. Yoshie, S. Sakaguchi, et al. Constitutive Expression of IDO by Dendritic Cells of Mesenteric Lymph Nodes: Functional Involvement of the CTLA-4/B7 and CCL22/CCR4 Interactions J. Immunol., November 1, 2009; 183(9): 5608 - 5614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D Thrasher and S. Crawley The biocontaminants and complexity of damp indoor spaces: more than what meets the eyes Toxicology and Industrial Health, October 1, 2009; 25(9-10): 583 - 615. [Abstract] [PDF]
|
|
|
|
|
|
M. Brenk, M. Scheler, S. Koch, J. Neumann, O. Takikawa, G. Hacker, T. Bieber, and D. von Bubnoff Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells J. Immunol., July 1, 2009; 183(1): 145 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Below, A. Konkel, C. Zeeck, C. Muller, C. Kohler, S. Engelmann, and J.-P. Hildebrandt Virulence factors of Staphylococcus aureus induce Erk-MAP kinase activation and c-Fos expression in S9 and 16HBE14o- human airway epithelial cells Am J Physiol Lung Cell Mol Physiol, March 1, 2009; 296(3): L470 - L479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Yen, C.-C. Lin, Y.-L. Chen, S.-S. Huang, H.-J. Yang, C.-P. Chang, H.-Y. Lei, and M.-D. Lai A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA Clin. Cancer Res., January 15, 2009; 15(2): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Orabona, M. T. Pallotta, C. Volpi, F. Fallarino, C. Vacca, R. Bianchi, M. L. Belladonna, M. C. Fioretti, U. Grohmann, and P. Puccetti SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis PNAS, December 30, 2008; 105(52): 20828 - 20833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation J. Immunol., October 15, 2008; 181(8): 5396 - 5404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Metz, J. B. DuHadaway, U. Kamasani, L. Laury-Kleintop, A. J. Muller, and G. C. Prendergast Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound D-1-Methyl-Tryptophan Cancer Res., August 1, 2007; 67(15): 7082 - 7087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. J. van der Marel, J. N. Samsom, M. Greuter, L. A. van Berkel, T. O'Toole, G. Kraal, and R. E. Mebius Blockade of IDO Inhibits Nasal Tolerance Induction J. Immunol., July 15, 2007; 179(2): 894 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liu, H. Dai, N. Wan, T. Wang, S. Bertera, M. Trucco, and Z. Dai Suppression of Memory CD8 T Cell Generation and Function by Tryptophan Catabolism J. Immunol., April 1, 2007; 178(7): 4260 - 4266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Y. Hou, A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. L. Mellor, G. C. Prendergast, and D. H. Munn Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses Cancer Res., January 15, 2007; 67(2): 792 - 801. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
